Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin and cognitive function

This article was originally published in The Tan Sheet

Executive Summary

Low-dose aspirin use does not protect older women from cognitive decline, according to a randomized, double-blind study published on the British Medical Journal's Web site April 27. Conducted by Jae Hee Kang, et al., Brigham and Women's Hospital in Boston, the nearly 10-year study evaluated 6,377 women aged 65 and older who were taking part in the Women's Health study. Subjects were divided into two treatment groups: low-dose aspirin and placebo. Cognitive performance measured at 5.6 years and 9.6 years of treatment were similar among the groups. Although results suggest category fluency was better in the aspirin group, authors stress the finding should be interpreted "with caution," concluding "other methods for preserving cognitive function in older people need to be investigated." A study in the April 18 issue of the Journal of the National Cancer Institute and a recent Consumers Union report finds aspirin use was associated with decreased risks of certain cancers and heart attack, respectively (1"The Tan Sheet" April 23, 2007, p. 8 and 2"The Tan Sheet" April 23, 2007, p. 10)...

Low-dose aspirin use does not protect older women from cognitive decline, according to a randomized, double-blind study published on the British Medical Journal's Web site April 27. Conducted by Jae Hee Kang, et al., Brigham and Women's Hospital in Boston, the nearly 10-year study evaluated 6,377 women aged 65 and older who were taking part in the Women's Health study. Subjects were divided into two treatment groups: low-dose aspirin and placebo. Cognitive performance measured at 5.6 years and 9.6 years of treatment were similar among the groups. Although results suggest category fluency was better in the aspirin group, authors stress the finding should be interpreted "with caution," concluding "other methods for preserving cognitive function in older people need to be investigated." A study in the April 18 issue of the Journal of the National Cancer Institute and a recent Consumers Union report finds aspirin use was associated with decreased risks of certain cancers and heart attack, respectively (1 p. 8 and 2 (Also see "Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union" - Pink Sheet, 23 Apr, 2007.) p. 10)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel